{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-25-001006","form_type":"8-K","ticker":"PLSE","cik":"0001625101","company_name":"PULSE BIOSCIENCES, INC.","filed_at":"2025-01-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.227616+00:00","generated_at":"2026-05-28T03:25:35.455102+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Pulse Biosciences appoints Paul LaViolette as CEO; grants 1.5M stock options with revenue/market cap milestones","bullets":["Paul LaViolette, former Co-Chairman, becomes CEO and President effective Jan 9, 2025.","Employment: $725k base salary, 70% target bonus, and option to purchase 1.5M shares at $18.43.","Options vest 30% time-based over 4 years; 70% performance-based tied to market cap ($3B–$9B) and GAAP revenue/margin targets.","Company also granted inducement options for 138,800 shares to 11 new employees at $18.55.","Pulse to present at JP Morgan Healthcare Conference Jan 15; nano-PFA cardiac systems in clinical studies."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-25-001006","json":"https://secwatch.observer/filing/0001437749-25-001006.json","markdown":"https://secwatch.observer/filing/0001437749-25-001006.md","text":"https://secwatch.observer/filing/0001437749-25-001006.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1625101/000143774925001006/0001437749-25-001006-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1625101/000143774925001006/plse20250109_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-28T03:25:35.455102+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"32233e9145","claim":"Paul A. LaViolette was appointed as Chief Executive Officer and President at PULSE BIOSCIENCES, INC..","evidence_excerpt":"The Board of Directors of Pulse Biosciences, Inc. (the “Company”) has appointed Paul A. LaViolette, current Co-Chairman of the Board, as Chief Executive Officer and President of the Company, effective as of January 9, 2025","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1625101/000143774925001006/0001437749-25-001006-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Executive Officer and President"}]}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}